bright minds biosciences

This Year in Psychedelics - 2021

Before we get into this recap of the biggest psychedelic news stories from 2021, I’d like to address the fact that this blog post is coming out a month late. Normally I strive to publish my yearly recaps on New Year’s Eve, but things have been really hectic on my end lately and I’ve been barely keeping up with putting out the weekly link roundups, much less creating monthly and yearly recaps or other types of content.

So I apologize for not getting this out into the world sooner. I’ve started to realize that I bit off way more than I can chew over the last year and fell behind on things here at Think Wilder. Here’s hoping 2022 will be a little more focused so I can meet my deadlines and get my work out in a timely manner for y’all to enjoy!

Just like last month’s recap, there is no video recap of this year’s psychedelic news recap up on YouTube. I’ll have another update about some changes coming to my YouTube channel that should hopefully be out later this week on my channel, so make sure you subscribe there if you’d like to be informed about things on that front.

Moving on to the main show, there was a ton of huge news in 2021. Without further ado, let’s jump into the news.

Policy

Wins

Nine U.S. cities decriminalized psychedelics:

When it comes to cannabis policies there were several successes at the state level, even though attempts to change things at the federal level were unsuccessful. Four states legalized weed:

In addition, Alabama legalized medical marijuana and New Jersey and Louisiana decriminalized cannabis.

Taking things a bit further, Baltimore, MD and Scotland decriminalized the use of all drugs.

The governors of Connecticut and Texas signed legislation that will enable the states to study the therapeutic potential of psychedelics. And New Zealand legalized drug checking, becoming the world’s first country to do so.

Industry

One of the biggest stories in the psychedelic industry involved the fight over patenting various aspects involving psychedelics. The one that probably stirred up the most discontent was when COMPASS Pathways submitted a patent application that attempted to claim the right to common, preexisting psychedelic therapy techniques. This prompted a discussion about patents in psychedelia, with many people wondering if companies should own the future of the field. COMPASS Pathways has five U.S. patents and a total of ten worldwide, so they are quickly claiming rights to a lot of intellectual property in the space. But not without a fight—last month a non-profit known as Freedom to Operate submitted a new legal filing that argues against COMPASS Pathways’ patent on its form of synthetic psilocybin based on the idea that it is not a novel invention. The results from this case will set a precedent for not just COMPASS Pathways but for other psychedelic companies as well.

Psychedelic companies started making waves on the stock markets around the world, with five companies joining the Nasdaq (Mindmed, atai Life Sciences, Field Trip Health, Enveric Biosciences, and Bright Minds Biosciences) and Cybin joining the New York Stock Exchange.

Psychedelic companies secured a historic amount of funding, estimated at a cool $2 billion.

A few other interesting stories in the realm of psychedelic industry from 2021:

Research

Published Studies

Several studies came out:

Future Studies

Looking ahead:

  • A study looking to treat tobacco addiction with psilocybin will receive federal funding

  • The NIH granted Yale nearly $200k to fund the studying of psilocybin for depression and obsessive-compulsive disorder

  • The Australian government earmarked $15 million for psychedelic research

  • The DEA has proposed a dramatic increase in the production of cannabis and psychedelics for research in 2022

Research Centers

A record-breaking number of psychedelic research centers were announced or opened:

In addition to these new psychedelic research centers, Harvard Law School’s Project on Psychedelics Law and Regulation will contribute to the effort to create evidence-based laws and policies involving psychedelics.

Harm Reduction

The FDA and CDC issued warnings to consumers about potential risks involving delta-8 THC, a relatively new psychoactive cannabinoid that has grown in popularity due to its widespread legality but remains essentially unregulated at this time. Apparently there has been a significant increase in reported adverse health effects from people using this drug.

However, before you go ahead and toss any of these products you may already own out of the window, it may be helpful to know that it’s not like people are getting poisoned. In fact, it’s far more likely that they are unintentionally getting high after using delta-8 THC because of misunderstandings, bad labeling, and a lack of experience.

The Fireside Project has been helping people process psychedelic experiences via its free peer support phone line since it launched last April, but the organization took things to the next level by releasing a psychedelic peer support app. Now psychonauts in need of support can find help on either the phone or via chat, which may be helpful for people who prefer one form of communication over another.

Drug checking is an essential practice for any responsible psychonaut, and new technologies are coming out that will ensure more innovative and accurate results than ever before. The popular harm reduction organization known as DanceSafe released a new ketamine test kit (called the Morris reagent) that was engineered to identify the difference between ketamine and common analogues like DCK and 2FDCK. And a startup called Miraculix took things one step further by creating rapid at-home test kits that can assess the potency of various psychoactive drugs, including MDMA, LSD, and psilocybin.

Harm reductionists have yet another tool that can be used to help psychonauts use drugs as safely as possible; a new app called Pill-iD lets users scan pills to see what they contain.

However, it’s not a perfect option because rather than find out what’s actually inside a pill, the app instead uses machine learning to cross-check the user’s image against a large database of scanned pills to provide details about what drug is actually contained within, the risk level from taking it, and any potential side effects.

So while it’s not advisable to rely solely on this new app to find out what’s inside your pill, it could help inform naïve users that there is a possibility they might have bought an adulterated drug. As I’ve tried to hammer home over and over again, it’s always advisable to use a reagent test kit to further rule out the possibility that your pills contain unwanted drugs and to properly weigh your substances before you take them.

Miscellaneous

What a year! Tons of new psychedelic research studies, a streak of drug policy reform wins, the growing psychedelic industry, and several important developments in psychedelic culture… last year was certainly a lot to take in.

Now that you’ve read my recap of the biggest psychedelic news from 2021, I’d like to recommend the following highlights from other publications that you might enjoy:

And lastly, I will leave you with the links to the annual psychedelic news recaps I’ve published over the last six years. I hope you have a wonderful 2022 and make sure you subscribe to my monthly newsletter to keep up-to-date with all the latest psychedelic news.

Previous Years in Psychedelics

That’s all for this year’s update. Remember to always test and weigh your drugs and until next time—keep thinking wilder.

Think Wilder is reader-supported. If you enjoyed this year’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

This Week in Psychedelics - 12.3.21

Cannabis

  • Home of Dubai, the United Arab Emirates, Ends Jail Time for Travelers with THC (High Times)

  • Mexico has a new marijuana legalization bill. Here’s what’s in it (Leafly)

  • Reps. Dave Joyce and Alexandria Ocasio-Cortez Introduce Legislation To Expunge Marijuana Records (NORML)

  • South Dakota's Governor Succeeds in Blocking Voter-Approved Marijuana Legalization (Reason)

  • Fentanyl-laced vape pens among teens concern after Tennessee high school incident (WKYT)

  • Record Number of Scientific Papers Published About Cannabis in 2021 (NORML)

  • Death sentences upheld for two men convicted of cannabis trafficking (Singapore Law Watch)

  • California rolls out plans to standardize cannabis testing statewide (Marijuana Business Daily)

  • Jamaican Government Launches ‘Good Ganja Sense’ Campaign To Debunk Marijuana Myths (Marijuana Moment)

  • Great News, Scientists Finally Figured Out Why Cannabis Smells 'Skunky' (ScienceAlert)

  • Texas Activists Turn In Signatures To Put Marijuana Decriminalization On Austin’s 2022 Ballot (Marijuana Moment)

  • Kentucky Lawmaker Pre-Files Marijuana Legalization Bills For 2022 Session (Marijuana Moment)

  • Colorado University Announces Groundbreaking Study on Cannabis and Exercise (High Times)

  • Massachusetts: Majority of Adults Say Marijuana Legalization Has Been “Positive” for the State (NORML)

LSD

  • Blotter paper should be included while measuring weight of LSD, rules Bombay HC (India Today)

  • How LSD changed The Beatles forever (Far Out Magazine)

Magic Mushrooms

  • New Study Suggests SSRI Drugs Can Be Used Safely with Psilocybin to Treat Depression (Psychedelic Spotlight)

  • Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress (Psilocybin Alpha)

  • U of M Medical School launches new mechanistic study of psilocybin (University of Minnesota)

Ayahuasca

  • Sexual Assault in the Amazon (The Cut)

Iboga

Novel Psychoactive Substances

  • MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation (Psilocybin Alpha)

  • Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (Psilocybin Alpha)

Nitrous Oxide

  • ‘Everyone’s gagging for it’ – how Britain got high on nitrous oxide (The Guardian)

  • Dozens of traffic accident deaths linked to laughing gas use (NL Times)

Ketamine

  • Ketamine review: Chemical restraints may have been ‘disproportionately’ used on ‘communities of color’ (KDVR)

  • As ketamine clinics emerge in Seattle to treat mental illness, so does debate about safety and regulations (The Seattle Times)

  • PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio (Psilocybin Alpha)

Miscellaneous

  • New York City Opens First Safe Consumption Sites For Illegal Drugs In The U.S. (Marijuana Moment)

  • Florida Lawmaker Files Bill To Decriminalize All Currently Illicit Drugs (Marijuana Moment)

  • Toronto May Be the Next City to Decriminalize Psychedelics and Other Drugs (Truffle Report)

  • Study Shows People Who Use Psychedelics Were Under Less Stress During Covid-19 Lockdowns (Forbes)

  • DEA Again Boosts 2022 Production Goals For Psychedelics Like Psilocybin, MDMA and DMT (Marijuana Moment)

  • People ‘microdosing’ psychedelics to improve wellbeing during pandemic, drug survey finds (The Independent)

  • Psychedelics may have long-term impact treating depression, mental illness - study (The Jerusalem Post)

  • Psychedelic Telemedicine Has Arrived. What Could Possibly Go Wrong? (VICE)

  • The Psychedelic Renaissance Is Ushering In a New Genre Of Electronic Music — And With It, New Revenue Streams (Billboard)

  • Holiday Gift Guide 2021: Gifts For The Psychedelic Explorer (Forbes)

  • Can ethics and sexual abuse allegations create backlash and impact the current psychedelic renaissance? (Chacruna)

  • Will the psychedelic revolution bypass people of color? (The Lens)

  • Celebrities: Are They Helping or Harming the Psychedelic Movement? (Psychedelic Spotlight)

  • Origin Therapeutics Portfolio Company Tripsitter has Commenced Trading on the Canadian Securities Exchange (GlobeNewswire)

  • Peter Thiel-backed psychedelic start-up increases stake in Compass Pathways (CNBC)

  • Microdosing Protocols: Microdosing Every Day vs. Every Other Day (DoubleBlind)

  • Editor’s Choice Award 2021-Best Study on Psychedelics and Neurochemistry (Psychedelic Science Review)

  • Novel Psychedelic Treatment Approach Bypasses Hallucinogenic Effects to Allow Widespread Adoption (Pharmacy Times)

  • Israeli start up makes pharmaceuticals out of psychedelic flora (i24 News)

  • Getting Ahead of the Psychedelics Supply Crunch (Truffle Report)

  • Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans (Psilocybin Alpha)

Think Wilder is reader-supported. If you enjoyed this week’s update, please consider helping out by becoming a patron, making a one-time donation, or sharing this post with a friend. Thank you for your support.

Disclaimer: "This Week in Psychedelics" does not censor or analyze the news links presented here. The purpose of this column is solely to catalog how psychedelics are presented by the mass media, which includes everything from the latest scientific research to misinformation.